The Absorb bioresorbable vascular scaffold (BVS) may be safe and effective for the treatment of patients with diabetes mellitus, according to the results of the Absorb Diabetic Substudy presented Oct. 31 at TCT 2016 and simultaneously published in JACC: Cardiovascular Interventions.

Dean J. Kereiakes, MD, FACC, et al., analyzed data from the ABSORB I, III, JAPAN and EXTEND studies on 754 patients with diabetes who received the Absorb BVS. The primary endpoint was target lesion failure at one-year follow-up compared with a performance goal of 12.7 percent.

The results of the substudy suggest the efficacy and safety of the Absorb BVS for treatment of diabetes patients. At one-year follow-up, the target lesion failure was 8.3 percent and scaffold thrombosis was observed in 2.3 percent of patients.

The authors of the study note that “although this work represents the largest clinical outcomes analysis to date of diabetic patients treated with the Absorb BVS, larger-scale direct comparative trials of Absorb versus Xience with long-term follow-up are required to better define relative outcomes between these devices in patients with diabetes mellitus.” 

Keywords: Transcatheter Cardiovascular Therapeutics, Absorbable Implants, Diabetes Mellitus, Drug-Eluting Stents, Follow-Up Studies, Thrombosis, Angina, Stable, Absorbable Implants, Coronary Artery Disease, Drug-Eluting Stents

< Back to Listings